Liposomes, nanoemulsions, lipid nanoparticles and polymeric nanoparticles have all shown promise in improving the therapeutic benefits of cannabinoids, but the full potential of these therapies has not yet been unlocked.

Employing nanoparticle formulation technology from the cutting edge of genetic medicine, Ascension Sciences (ASI) is developing cannabinoid nano delivery platforms and techniques for the pharma and nutraceutical industries.

ASI’s R&D and formulation development services are an efficient option for research-driven firms that require the advantages of nanoparticle delivery for their active ingredients.


  • Nanoparticle Characterization: Benchmark particle size, stability, encapsulation efficiency and release profile.
  • Nanoparticle Development: Excipient & active ingredient screening.
  • Pre-clinical Custom Formulation Development: With a specific therapeutic end-point in mind, we design a nanoparticle formulation that meets your needs.

We are seeking collaborators and channel partners

to bring formulations to the patients that need them most.